# TRACC

Source: https://onco.cc/trials/tracc/  
OnCo record `tracc` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A UK study following 1,000 people after bowel cancer surgery with repeated blood tests for tumour DNA, to see how well a positive predicts the cancer coming back and whether the result can guide chemotherapy.

## Summary

TRACC is the Royal Marsden-led UK programme tracking ctDNA after surgery for early colorectal cancer. The registry lists it as an observational study of 1,000 participants that started on 5 December 2016, still recruiting, with a primary completion date of 31 July 2029 and study completion of 31 July 2031. It is one of the three large national colorectal programmes (with CIRCULATE-Japan and CIRCULATE-US) whose readouts decide whether ctDNA-guided adjuvant therapy becomes standard outside a trial.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-21
- Also known as: Tracking mutations in cell free tumour DNA to predict relapse in early colorectal cancer
- Tags: ctdna-roadmap
- Registry id: NCT04050345
- Phase: observational
- Setting: Early colorectal cancer after curative surgery in the United Kingdom: serial ctDNA to predict relapse, with a later part that uses the result to guide adjuvant chemotherapy
- Sponsor: Royal Marsden NHS Foundation Trust
- Enrolled: 1000

## Sources

- ClinicalTrials.gov NCT04050345: https://clinicaltrials.gov/study/NCT04050345

## Connected records

- trials: [ALTAIR](https://onco.cc/trials/altair/), [CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)](https://onco.cc/trials/circulate-japan/), [CIRCULATE-US](https://onco.cc/trials/circulate-us/), [DYNAMIC](https://onco.cc/trials/dynamic/), [DYNAMIC-III](https://onco.cc/trials/dynamic-iii/)
- roadmaps: [ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment](https://onco.cc/roadmaps/ctdna-tests/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- institutions: [Bowel Cancer UK](https://onco.cc/institutions/bowel-cancer-uk/), [The Royal Marsden](https://onco.cc/institutions/royal-marsden/)
- terms: [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/), [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/)
- people: [Ian Chau](https://onco.cc/people/ian-chau/), [Naureen Starling](https://onco.cc/people/naureen-starling/)
- key papers: [Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study](https://onco.cc/key-papers/paper-tracc-clin-cancer-res-2024/)

---
JSON: https://onco.cc/api/v1/entities/tracc.json